| Net loss | 23.75M |
| Amortization of deferred revenue | -3.6M |
| Depreciation | 1.84M |
| Amortization of intangibles | 5.58M |
| Amortization of premium and discount on investments, net | -801K |
| Stock-based employee compensation | 5.4M |
| Stock-based non-employee compensation | |
| Non-cash expense under a materials agreement | |
| Stock-based compensation to Board of Directors and Scientific Advisory Board | |
| Loss on stock warrant liability | |
| Retirement plan benefit expense | |
| Accounts receivable | 6.75M |
| Inventory | -3.72M |
| Other current assets | |
| Other assets | |
| Accounts payable and accrued expenses | -5.63M |
| Deferred revenue | 2.25M |
| Other current liabilities | |
| Net cash provided by (used in) operating activities | 36.23M |
| Purchase of property and equipment | -2.16M |
| Purchase of intangibles | -96.03M |
| Purchase of short-term investments | -325.23M |
| Proceeds from sale of short-term investments | 364.02M |
| Net cash used in investing activities | -59.4M |
| Proceeds from the issuance of common stock | 202K |
| Proceeds from the exercise of common stock options and warrants | |
| Payment of withholding taxes related to stock-based employee compensation | |
| Net cash provided by financing activities | -4.41M |
| INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | -27.58M |
| CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD | 97.51M |
| CASH AND CASH EQUIVALENTS, END OF PERIOD | 69.93M |
| Unrealized gain (loss) on available-for-sale securities | |
| Common stock issued to Board of Directors and Scientific Advisory Board that was earned in a previous period | |
| Common stock issued to employees that was accrued for in a previous period, net of shares withheld for taxes | |
| Common stock issued for royalties that was earned in a previous period | |
| Fair value of stock warrant liability reclassified to shareholders' equity upon exercise | |